Therapeutic potency of pharmacological adenosine receptors agonist/antagonist on cancer cell apoptosis in tumor microenvironment, current status, and perspectives

J Cell Physiol. 2019 Mar;234(3):2329-2336. doi: 10.1002/jcp.27249. Epub 2018 Sep 7.

Abstract

The hypoxic niche of tumor leads to a tremendous increase in the extracellular adenosine concentration through alteration of adenosine metabolism in the tumor microenvironment (TME). This consequently affects cancer progression, local immune responses, and apoptosis of tumor cells. Regulatory effect of adenosine on apoptosis in TME depends on the cancer cell type, pharmacological characteristics of adenosine receptor subtypes, and the adenosine concentration in the tumor niche. Exploiting specific pharmacological adenosine receptor agonist and antagonist inducing apoptosis in cancer cells can be considered as a proper procedure to control cancer progression. This review summarizes the regulatory role of adenosine in cancer cell apoptosis for a better understanding, and hence better management of the disease.

Keywords: adenosine; adenosine receptors; apoptosis; cancer.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Adenosine Triphosphate / genetics
  • Apoptosis / drug effects
  • Neoplasms / drug therapy*
  • Neoplasms / genetics
  • Neoplasms / pathology
  • Purinergic P1 Receptor Agonists / therapeutic use*
  • Purinergic P1 Receptor Antagonists / therapeutic use*
  • Receptors, Purinergic P1 / genetics*
  • Signal Transduction / drug effects
  • Tumor Microenvironment / drug effects

Substances

  • Purinergic P1 Receptor Agonists
  • Purinergic P1 Receptor Antagonists
  • Receptors, Purinergic P1
  • Adenosine Triphosphate